{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:17:00Z","timestamp":1788812220342,"version":"build-2803163510"},"reference-count":28,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["Z200014"],"award-info":[{"award-number":["Z200014"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Risk &amp; Safety in Medicine"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intraocular pressure (IOP)-lowering drugs are essential for glaucoma treatment but can cause ocular and systemic adverse events (AEs). This study utilizes the FDA Adverse Event Reporting System (FAERS) database to investigate the AE signals associated with these drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis of FAERS data from Q1 2004 to Q4 2023 was conducted. A total of 107,604 AE reports related to IOP-lowering drugs were analyzed using four signal detection methods: ROR, PRR, BCPNN, and MGPS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Significant AE signals were identified, including ocular surface damage linked to preservatives, cardiovascular disorders associated with \u03b2-blockers, and ear-related issues with carbonic anhydrase inhibitors and prostaglandin analogs. Carteolol showed a new signal for hepatobiliary disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study highlights key safety concerns with IOP-lowering drugs, including ocular, cardiovascular, and ear-related AEs. These findings emphasize the need for careful monitoring and further research to confirm these associations and mitigate risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09246479251414278","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T14:25:42Z","timestamp":1767363942000},"page":"315-327","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Ocular adverse reactions associated with intraocular pressure-reducing drugs: An analysis of the FDA adverse event reporting system (FAERS)"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3042-6593","authenticated-orcid":false,"given":"Chengzhi","family":"Liu","sequence":"first","affiliation":[{"name":"Capital Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaihao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Capital Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Capital Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoyue","family":"Dong","sequence":"additional","affiliation":[{"name":"Capital Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Shen","sequence":"additional","affiliation":[{"name":"Capital Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Liu","sequence":"additional","affiliation":[{"name":"Capital Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xusheng","family":"Cao","sequence":"additional","affiliation":[{"name":"Capital Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1328498"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-03342-4"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2021.1922384"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/08164622.2021.1964331"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1502047"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","unstructured":"Liu C Wang X Zhou C et al. A real-world disproportionality analysis of cidofovir from the FDA adverse event reporting system (FAERS) database. Expet Opin Drug Saf 2025; Online ahead of print.","DOI":"10.1080\/14740338.2025.2490271"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2006.pto_286.x"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.4103\/TOPH.TOPH_4_23"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2010.03.001"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000544"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/ftox.2023.1067942"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1225718"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-009-1092-8"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/567387"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389200222666210614112529"},{"issue":"6","key":"e_1_3_4_19_2","first-page":"e25815","article-title":"Bradycardia from a non-selective beta-adrenergic antagonist, timolol, applied ophthalmologically for glaucoma","volume":"14","author":"May G","year":"2022","unstructured":"May G, Miller D, Fuchs D. Bradycardia from a non-selective beta-adrenergic antagonist, timolol, applied ophthalmologically for glaucoma. Cureus 2022; 14(6): e25815.","journal-title":"Cureus"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10126-017-9763-7"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12070-011-0151-8"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijporl.2013.03.025"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2005.05.043"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-024-03823-w"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/20420986241285929"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.13.9.17"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.131"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80007-6"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/0018578719882323"}],"container-title":["International Journal of Risk &amp; Safety in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479251414278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09246479251414278","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479251414278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T10:20:47Z","timestamp":1786098047000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09246479251414278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/09246479251414278"],"URL":"https:\/\/doi.org\/10.1177\/09246479251414278","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/09246479251414278\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479251414278\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479251414278\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479251414278\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479251414278\/v1\/decision1","asserted-by":"object"}]},"ISSN":["0924-6479","1878-6847"],"issn-type":[{"value":"0924-6479","type":"print"},{"value":"1878-6847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]}}}